 Laurence Levine
Concepts (470)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Penile Induration | 73 | 2018 | 74 | 28.230 |
Why?
| | Penis | 40 | 2018 | 49 | 12.810 |
Why?
| | Erectile Dysfunction | 33 | 2018 | 40 | 9.620 |
Why?
| | Penile Prosthesis | 22 | 2018 | 22 | 6.620 |
Why?
| | Penile Implantation | 10 | 2018 | 10 | 4.690 |
Why?
| | Spermatic Cord | 10 | 2018 | 12 | 4.570 |
Why?
| | Male | 151 | 2018 | 14829 | 4.350 |
Why?
| | Denervation | 9 | 2018 | 19 | 4.120 |
Why?
| | Verapamil | 15 | 2014 | 34 | 4.080 |
Why?
| | Urologic Surgical Procedures, Male | 13 | 2017 | 17 | 3.570 |
Why?
| | Traction | 12 | 2018 | 21 | 3.470 |
Why?
| | Patient Satisfaction | 22 | 2018 | 233 | 3.460 |
Why?
| | Microbial Collagenase | 7 | 2018 | 9 | 3.410 |
Why?
| | Penile Erection | 20 | 2016 | 23 | 3.350 |
Why?
| | Humans | 155 | 2018 | 25535 | 3.340 |
Why?
| | Urethra | 6 | 2017 | 16 | 3.320 |
Why?
| | Testicular Diseases | 7 | 2016 | 10 | 3.300 |
Why?
| | Urethral Stricture | 6 | 2017 | 8 | 3.120 |
Why?
| | Microsurgery | 9 | 2018 | 42 | 2.870 |
Why?
| | Vasectomy | 4 | 2018 | 5 | 2.860 |
Why?
| | Penile Diseases | 4 | 2017 | 5 | 2.830 |
Why?
| | Middle Aged | 75 | 2018 | 9566 | 2.620 |
Why?
| | Adult | 73 | 2018 | 8368 | 2.560 |
Why?
| | Retrospective Studies | 30 | 2018 | 2563 | 2.380 |
Why?
| | Scrotum | 4 | 2017 | 8 | 2.320 |
Why?
| | Mitomycin | 3 | 2017 | 12 | 2.280 |
Why?
| | Treatment Outcome | 36 | 2018 | 3191 | 2.190 |
Why?
| | Injections, Intralesional | 17 | 2018 | 28 | 2.160 |
Why?
| | Priapism | 8 | 2016 | 9 | 2.150 |
Why?
| | Chronic Pain | 4 | 2016 | 71 | 2.120 |
Why?
| | Pain, Postoperative | 5 | 2018 | 202 | 1.950 |
Why?
| | Algorithms | 8 | 2018 | 380 | 1.900 |
Why?
| | Prostatectomy | 6 | 2016 | 22 | 1.700 |
Why?
| | Postoperative Complications | 13 | 2018 | 918 | 1.660 |
Why?
| | Aged | 45 | 2018 | 8468 | 1.650 |
Why?
| | Ketoconazole | 3 | 2013 | 6 | 1.590 |
Why?
| | Pelvic Pain | 2 | 2016 | 11 | 1.510 |
Why?
| | Physical Therapy Modalities | 2 | 2016 | 68 | 1.490 |
Why?
| | Urinary Bladder Diseases | 3 | 2015 | 9 | 1.480 |
Why?
| | Intermittent Urethral Catheterization | 2 | 2015 | 2 | 1.450 |
Why?
| | Contracture | 2 | 2015 | 13 | 1.430 |
Why?
| | Vasodilator Agents | 6 | 2011 | 28 | 1.400 |
Why?
| | Calcium Channel Blockers | 5 | 2015 | 37 | 1.370 |
Why?
| | Hypogonadism | 4 | 2014 | 4 | 1.310 |
Why?
| | Pelvis | 3 | 2017 | 23 | 1.260 |
Why?
| | Testosterone | 5 | 2013 | 34 | 1.240 |
Why?
| | Pain, Intractable | 3 | 2012 | 16 | 1.230 |
Why?
| | Pericardium | 5 | 2012 | 23 | 1.210 |
Why?
| | Phosphodiesterase 5 Inhibitors | 3 | 2018 | 4 | 1.190 |
Why?
| | Phosphodiesterase Inhibitors | 7 | 2011 | 18 | 1.180 |
Why?
| | Piperazines | 8 | 2012 | 83 | 1.170 |
Why?
| | Practice Guidelines as Topic | 10 | 2016 | 332 | 1.160 |
Why?
| | Reconstructive Surgical Procedures | 4 | 2016 | 175 | 1.140 |
Why?
| | Suction | 6 | 2012 | 42 | 1.100 |
Why?
| | Follow-Up Studies | 17 | 2014 | 1754 | 1.080 |
Why?
| | Prospective Studies | 14 | 2018 | 1508 | 1.050 |
Why?
| | Urology | 4 | 2014 | 14 | 1.030 |
Why?
| | Pelvic Floor | 2 | 2016 | 8 | 0.990 |
Why?
| | Young Adult | 10 | 2018 | 1791 | 0.960 |
Why?
| | Collagenases | 6 | 2011 | 22 | 0.940 |
Why?
| | Mouth Mucosa | 3 | 2008 | 13 | 0.940 |
Why?
| | Combined Modality Therapy | 6 | 2018 | 437 | 0.890 |
Why?
| | Adolescent | 14 | 2018 | 2287 | 0.890 |
Why?
| | Psychotherapy | 1 | 2018 | 39 | 0.870 |
Why?
| | Testis | 4 | 2008 | 11 | 0.850 |
Why?
| | Urogenital Surgical Procedures | 1 | 2017 | 1 | 0.850 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2017 | 23 | 0.830 |
Why?
| | Pain | 5 | 2013 | 272 | 0.830 |
Why?
| | Sutures | 1 | 2017 | 35 | 0.820 |
Why?
| | Sexual Behavior | 5 | 2016 | 51 | 0.810 |
Why?
| | Digital Rectal Examination | 1 | 2016 | 4 | 0.800 |
Why?
| | Epididymis | 4 | 2016 | 12 | 0.780 |
Why?
| | Vascular Surgical Procedures | 1 | 2016 | 44 | 0.760 |
Why?
| | Spermatozoa | 3 | 2003 | 9 | 0.760 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2016 | 23 | 0.760 |
Why?
| | Nicardipine | 1 | 2015 | 5 | 0.750 |
Why?
| | Free Radical Scavengers | 1 | 2015 | 12 | 0.750 |
Why?
| | Superoxide Dismutase | 1 | 2015 | 19 | 0.740 |
Why?
| | Oligospermia | 3 | 2003 | 3 | 0.740 |
Why?
| | Recurrence | 7 | 2017 | 330 | 0.740 |
Why?
| | Testicular Hydrocele | 2 | 2012 | 4 | 0.720 |
Why?
| | Ultrasonography, Doppler, Duplex | 6 | 2018 | 17 | 0.720 |
Why?
| | Iontophoresis | 4 | 2011 | 8 | 0.720 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 91 | 0.720 |
Why?
| | Anticonvulsants | 1 | 2016 | 99 | 0.710 |
Why?
| | Postoperative Period | 4 | 2017 | 175 | 0.710 |
Why?
| | Impotence, Vasculogenic | 3 | 2010 | 4 | 0.700 |
Why?
| | Ischemia | 3 | 2013 | 26 | 0.690 |
Why?
| | Quality of Life | 4 | 2016 | 509 | 0.690 |
Why?
| | Vacuum | 6 | 2018 | 6 | 0.680 |
Why?
| | Prosthesis Design | 7 | 2018 | 420 | 0.680 |
Why?
| | Radiotherapy | 1 | 2014 | 63 | 0.660 |
Why?
| | 14-alpha Demethylase Inhibitors | 1 | 2013 | 1 | 0.660 |
Why?
| | Sulfones | 8 | 2012 | 25 | 0.630 |
Why?
| | Homosexuality, Male | 1 | 2013 | 15 | 0.620 |
Why?
| | Calcinosis | 1 | 2013 | 47 | 0.620 |
Why?
| | Prosthesis Failure | 2 | 2012 | 464 | 0.620 |
Why?
| | Genital Diseases, Male | 1 | 2012 | 5 | 0.610 |
Why?
| | Sclerotherapy | 1 | 2012 | 2 | 0.610 |
Why?
| | Doxycycline | 1 | 2012 | 25 | 0.600 |
Why?
| | Pain Measurement | 5 | 2016 | 404 | 0.590 |
Why?
| | Nerve Block | 1 | 2012 | 53 | 0.560 |
Why?
| | Cystitis | 4 | 1993 | 9 | 0.550 |
Why?
| | Administration, Oral | 4 | 2015 | 150 | 0.550 |
Why?
| | Ultrasonography | 6 | 2011 | 169 | 0.550 |
Why?
| | Pentoxifylline | 4 | 2011 | 8 | 0.520 |
Why?
| | Pain Management | 3 | 2017 | 108 | 0.520 |
Why?
| | Equipment and Supplies | 2 | 2008 | 14 | 0.520 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2014 | 508 | 0.520 |
Why?
| | Drug Resistance | 1 | 2010 | 62 | 0.510 |
Why?
| | Double-Blind Method | 8 | 2013 | 498 | 0.510 |
Why?
| | Transsexualism | 1 | 2010 | 3 | 0.510 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2012 | 294 | 0.500 |
Why?
| | Attitude of Health Personnel | 2 | 2012 | 162 | 0.490 |
Why?
| | Clomiphene | 1 | 2009 | 1 | 0.490 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2009 | 4 | 0.490 |
Why?
| | Luteinizing Hormone | 1 | 2009 | 8 | 0.490 |
Why?
| | Infertility, Male | 1 | 2009 | 5 | 0.490 |
Why?
| | Follicle Stimulating Hormone | 1 | 2009 | 18 | 0.480 |
Why?
| | Pilot Projects | 5 | 2015 | 373 | 0.480 |
Why?
| | Fibrosis | 3 | 2016 | 50 | 0.480 |
Why?
| | Sperm Count | 2 | 2001 | 3 | 0.470 |
Why?
| | Hormone Replacement Therapy | 1 | 2009 | 35 | 0.470 |
Why?
| | Prednisone | 1 | 2009 | 70 | 0.470 |
Why?
| | Glucocorticoids | 1 | 2009 | 65 | 0.460 |
Why?
| | Tissue Inhibitor of Metalloproteinases | 1 | 2008 | 7 | 0.440 |
Why?
| | Autonomic Denervation | 1 | 2008 | 1 | 0.440 |
Why?
| | Carboprost | 3 | 1993 | 3 | 0.440 |
Why?
| | Tromethamine | 3 | 1993 | 4 | 0.440 |
Why?
| | Cyclophosphamide | 4 | 1993 | 54 | 0.440 |
Why?
| | Matrix Metalloproteinases | 1 | 2008 | 31 | 0.440 |
Why?
| | Social Adjustment | 1 | 2008 | 32 | 0.440 |
Why?
| | Primary Health Care | 2 | 2007 | 80 | 0.430 |
Why?
| | Self Concept | 1 | 2008 | 48 | 0.430 |
Why?
| | Interleukin-1beta | 1 | 2008 | 52 | 0.430 |
Why?
| | Lichen Sclerosus et Atrophicus | 1 | 2007 | 1 | 0.430 |
Why?
| | Body Image | 1 | 2008 | 36 | 0.430 |
Why?
| | Postoperative Care | 4 | 2012 | 124 | 0.420 |
Why?
| | Referral and Consultation | 3 | 2016 | 84 | 0.420 |
Why?
| | Trifluoperazine | 1 | 2007 | 4 | 0.420 |
Why?
| | Wounds, Nonpenetrating | 1 | 2007 | 19 | 0.420 |
Why?
| | Magnesium Sulfate | 1 | 2007 | 9 | 0.420 |
Why?
| | Wounds and Injuries | 1 | 2007 | 49 | 0.410 |
Why?
| | Family Practice | 1 | 2007 | 21 | 0.410 |
Why?
| | Expert Testimony | 4 | 2010 | 13 | 0.410 |
Why?
| | Urologic Surgical Procedures | 3 | 2018 | 7 | 0.410 |
Why?
| | Sperm Motility | 1 | 2006 | 2 | 0.400 |
Why?
| | Transforming Growth Factor beta | 1 | 2008 | 137 | 0.400 |
Why?
| | Rupture | 3 | 2014 | 104 | 0.390 |
Why?
| | Clostridium histolyticum | 3 | 2014 | 3 | 0.390 |
Why?
| | Evidence-Based Medicine | 6 | 2010 | 194 | 0.390 |
Why?
| | United States | 6 | 2014 | 1978 | 0.380 |
Why?
| | Clinical Competence | 2 | 2012 | 233 | 0.370 |
Why?
| | Aged, 80 and over | 9 | 2017 | 4302 | 0.360 |
Why?
| | Prevalence | 3 | 2013 | 477 | 0.360 |
Why?
| | Purines | 8 | 2012 | 30 | 0.350 |
Why?
| | Drug Administration Schedule | 3 | 2014 | 251 | 0.350 |
Why?
| | Gels | 3 | 2015 | 11 | 0.340 |
Why?
| | Anemia, Sickle Cell | 2 | 2013 | 10 | 0.320 |
Why?
| | Risk Factors | 5 | 2016 | 2192 | 0.320 |
Why?
| | Prosthesis-Related Infections | 2 | 2017 | 176 | 0.320 |
Why?
| | Endoscopy | 2 | 2017 | 157 | 0.320 |
Why?
| | Abdominal Neoplasms | 1 | 2003 | 10 | 0.310 |
Why?
| | Administration, Topical | 3 | 2015 | 20 | 0.310 |
Why?
| | Tissue and Organ Harvesting | 1 | 2003 | 25 | 0.310 |
Why?
| | Anesthetics, Local | 2 | 2016 | 81 | 0.310 |
Why?
| | Clinical Protocols | 2 | 2013 | 58 | 0.310 |
Why?
| | Antioxidants | 1 | 2003 | 70 | 0.300 |
Why?
| | Esophageal Neoplasms | 1 | 2003 | 54 | 0.300 |
Why?
| | Carcinoma, Renal Cell | 1 | 2003 | 75 | 0.290 |
Why?
| | Time Factors | 5 | 2015 | 1667 | 0.290 |
Why?
| | Patient Compliance | 2 | 2018 | 198 | 0.290 |
Why?
| | Animals | 8 | 2017 | 4767 | 0.280 |
Why?
| | Varicocele | 2 | 2001 | 3 | 0.280 |
Why?
| | Skin Transplantation | 3 | 2014 | 21 | 0.280 |
Why?
| | Recovery of Function | 4 | 2018 | 286 | 0.270 |
Why?
| | Colchicine | 3 | 2011 | 7 | 0.270 |
Why?
| | Hemorrhage | 2 | 1992 | 67 | 0.270 |
Why?
| | Interferons | 2 | 2011 | 18 | 0.270 |
Why?
| | Semen | 1 | 2001 | 4 | 0.270 |
Why?
| | Remission Induction | 3 | 2012 | 121 | 0.270 |
Why?
| | Ejaculation | 2 | 2018 | 6 | 0.260 |
Why?
| | Tissue Transplantation | 2 | 2011 | 22 | 0.250 |
Why?
| | Papaverine | 3 | 2011 | 4 | 0.250 |
Why?
| | Carnitine | 2 | 2011 | 5 | 0.250 |
Why?
| | Arginine | 2 | 2011 | 17 | 0.250 |
Why?
| | Catheterization | 2 | 1997 | 61 | 0.240 |
Why?
| | Electric Stimulation Therapy | 2 | 2011 | 43 | 0.240 |
Why?
| | Ultrasonography, Doppler, Color | 2 | 1996 | 9 | 0.240 |
Why?
| | Prostatic Neoplasms | 4 | 2014 | 126 | 0.240 |
Why?
| | Injections | 3 | 2018 | 56 | 0.230 |
Why?
| | Consensus | 3 | 2016 | 47 | 0.230 |
Why?
| | Cohort Studies | 3 | 2013 | 1527 | 0.230 |
Why?
| | Urological Agents | 1 | 2018 | 2 | 0.230 |
Why?
| | Orgasm | 1 | 2018 | 8 | 0.230 |
Why?
| | Child | 5 | 2008 | 1315 | 0.230 |
Why?
| | Coitus | 1 | 2018 | 4 | 0.230 |
Why?
| | PubMed | 1 | 2018 | 12 | 0.230 |
Why?
| | Drug Therapy, Combination | 3 | 2011 | 249 | 0.220 |
Why?
| | Personal Satisfaction | 1 | 2018 | 43 | 0.220 |
Why?
| | Transplants | 1 | 2017 | 11 | 0.220 |
Why?
| | Specimen Handling | 1 | 1998 | 46 | 0.210 |
Why?
| | Surgeons | 1 | 2018 | 29 | 0.210 |
Why?
| | Physical Examination | 2 | 2012 | 106 | 0.210 |
Why?
| | Surgical Flaps | 2 | 1998 | 56 | 0.200 |
Why?
| | Age Factors | 3 | 2011 | 784 | 0.200 |
Why?
| | Reperfusion | 1 | 2016 | 12 | 0.200 |
Why?
| | Anastomosis, Surgical | 3 | 2007 | 49 | 0.200 |
Why?
| | Lung Neoplasms | 1 | 2003 | 696 | 0.200 |
Why?
| | Antibiotic Prophylaxis | 1 | 2017 | 33 | 0.200 |
Why?
| | Vasovasostomy | 1 | 2016 | 1 | 0.190 |
Why?
| | Orchiectomy | 1 | 2016 | 5 | 0.190 |
Why?
| | Urethral Diseases | 1 | 1996 | 3 | 0.190 |
Why?
| | Severity of Illness Index | 3 | 2018 | 1105 | 0.190 |
Why?
| | Self Care | 1 | 1997 | 101 | 0.190 |
Why?
| | Papillomaviridae | 1 | 1996 | 28 | 0.190 |
Why?
| | Oils | 1 | 2015 | 1 | 0.190 |
Why?
| | Tumor Virus Infections | 1 | 1996 | 19 | 0.190 |
Why?
| | Papillomavirus Infections | 1 | 1996 | 32 | 0.190 |
Why?
| | History, 20th Century | 1 | 2016 | 87 | 0.190 |
Why?
| | Research Design | 2 | 2007 | 183 | 0.180 |
Why?
| | Myofibroblasts | 1 | 2015 | 3 | 0.180 |
Why?
| | Interferon-alpha | 1 | 1996 | 81 | 0.180 |
Why?
| | Transforming Growth Factor alpha | 1 | 2015 | 7 | 0.180 |
Why?
| | Pregnancy | 3 | 2003 | 361 | 0.180 |
Why?
| | Prognosis | 3 | 2012 | 837 | 0.180 |
Why?
| | Product Surveillance, Postmarketing | 2 | 2008 | 17 | 0.180 |
Why?
| | Prosthesis Implantation | 1 | 2015 | 43 | 0.180 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2014 | 27 | 0.170 |
Why?
| | Disease Management | 1 | 2016 | 112 | 0.170 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 37 | 0.170 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2014 | 28 | 0.170 |
Why?
| | Collagen | 1 | 2015 | 110 | 0.170 |
Why?
| | Hematoma | 1 | 2014 | 18 | 0.170 |
Why?
| | Female | 11 | 2013 | 15179 | 0.170 |
Why?
| | Software | 1 | 1994 | 55 | 0.170 |
Why?
| | Hypopituitarism | 1 | 2014 | 3 | 0.170 |
Why?
| | Medical Records | 1 | 2014 | 37 | 0.170 |
Why?
| | Nitric Oxide | 1 | 2015 | 102 | 0.170 |
Why?
| | Reactive Oxygen Species | 1 | 2015 | 124 | 0.170 |
Why?
| | Circumcision, Male | 1 | 2014 | 7 | 0.170 |
Why?
| | Disease Progression | 2 | 2011 | 727 | 0.170 |
Why?
| | Hematuria | 2 | 1993 | 15 | 0.170 |
Why?
| | Amputation, Traumatic | 2 | 2010 | 4 | 0.170 |
Why?
| | Polycystic Kidney Diseases | 1 | 1994 | 4 | 0.160 |
Why?
| | Carotid Artery, Internal | 1 | 2014 | 25 | 0.160 |
Why?
| | Carotid Artery Diseases | 1 | 2014 | 35 | 0.160 |
Why?
| | Leuprolide | 1 | 1993 | 4 | 0.160 |
Why?
| | Monitoring, Physiologic | 2 | 2009 | 85 | 0.160 |
Why?
| | Managed Care Programs | 1 | 2013 | 11 | 0.160 |
Why?
| | Ureter | 1 | 1993 | 25 | 0.150 |
Why?
| | Arteries | 3 | 2002 | 20 | 0.150 |
Why?
| | Splints | 2 | 2004 | 2 | 0.150 |
Why?
| | Constriction | 2 | 2004 | 4 | 0.150 |
Why?
| | Chronic Disease | 2 | 2008 | 465 | 0.150 |
Why?
| | Sexuality | 1 | 2013 | 19 | 0.150 |
Why?
| | Urinary Tract | 1 | 1992 | 1 | 0.150 |
Why?
| | Intracranial Aneurysm | 1 | 2014 | 79 | 0.150 |
Why?
| | Mesentery | 1 | 1992 | 6 | 0.150 |
Why?
| | Connective Tissue | 1 | 2012 | 28 | 0.150 |
Why?
| | Kidney Neoplasms | 1 | 1994 | 104 | 0.150 |
Why?
| | Medical History Taking | 2 | 2003 | 23 | 0.140 |
Why?
| | Ligation | 2 | 2006 | 32 | 0.140 |
Why?
| | Stents | 1 | 2014 | 149 | 0.140 |
Why?
| | Drug Implants | 1 | 2012 | 13 | 0.140 |
Why?
| | Reoperation | 2 | 2017 | 752 | 0.140 |
Why?
| | Kidney Transplantation | 1 | 1994 | 121 | 0.140 |
Why?
| | Depressive Disorder | 1 | 2014 | 208 | 0.140 |
Why?
| | Circadian Rhythm | 1 | 1995 | 259 | 0.140 |
Why?
| | Adenocarcinoma | 1 | 1994 | 220 | 0.140 |
Why?
| | Hypertension, Pulmonary | 1 | 2012 | 22 | 0.140 |
Why?
| | Alprostadil | 1 | 1991 | 11 | 0.140 |
Why?
| | Emergency Service, Hospital | 1 | 2013 | 135 | 0.140 |
Why?
| | Linear Models | 1 | 2012 | 257 | 0.140 |
Why?
| | 4-Aminobenzoic Acid | 1 | 2011 | 1 | 0.140 |
Why?
| | Body Weights and Measures | 1 | 2011 | 7 | 0.140 |
Why?
| | Placebos | 1 | 2011 | 82 | 0.140 |
Why?
| | Intestines | 1 | 1992 | 102 | 0.140 |
Why?
| | Electroconvulsive Therapy | 1 | 2011 | 17 | 0.140 |
Why?
| | Tamoxifen | 1 | 2011 | 28 | 0.130 |
Why?
| | Vitamin E | 1 | 2011 | 50 | 0.130 |
Why?
| | Organ Size | 1 | 2011 | 102 | 0.130 |
Why?
| | Prostaglandins F, Synthetic | 1 | 1990 | 1 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 1 | 2011 | 80 | 0.130 |
Why?
| | Sexology | 1 | 2010 | 1 | 0.130 |
Why?
| | Wounds, Penetrating | 1 | 2010 | 8 | 0.130 |
Why?
| | Replantation | 1 | 2010 | 7 | 0.130 |
Why?
| | Medicine | 1 | 2010 | 9 | 0.130 |
Why?
| | Transplantation, Autologous | 2 | 2008 | 193 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 2 | 2007 | 1037 | 0.120 |
Why?
| | Drug Dosage Calculations | 1 | 2009 | 7 | 0.120 |
Why?
| | Drug Costs | 1 | 2009 | 16 | 0.120 |
Why?
| | Urination Disorders | 1 | 1989 | 6 | 0.120 |
Why?
| | Carcinoma, Transitional Cell | 1 | 1989 | 14 | 0.120 |
Why?
| | Health Status Indicators | 1 | 2010 | 83 | 0.120 |
Why?
| | Urinary Bladder Neoplasms | 1 | 1989 | 31 | 0.120 |
Why?
| | Risk Assessment | 2 | 2012 | 669 | 0.120 |
Why?
| | Smoking | 1 | 1990 | 167 | 0.110 |
Why?
| | Heart Failure | 1 | 2012 | 176 | 0.110 |
Why?
| | Actinomycosis | 1 | 1988 | 3 | 0.110 |
Why?
| | Retroperitoneal Space | 1 | 1988 | 13 | 0.110 |
Why?
| | Penicillins | 1 | 1988 | 11 | 0.110 |
Why?
| | Social Isolation | 1 | 2008 | 19 | 0.110 |
Why?
| | Regional Blood Flow | 3 | 1995 | 19 | 0.110 |
Why?
| | Darkness | 1 | 2008 | 19 | 0.110 |
Why?
| | Sclerosing Solutions | 1 | 1988 | 3 | 0.110 |
Why?
| | Tetracycline | 1 | 1988 | 5 | 0.110 |
Why?
| | Feedback | 1 | 2008 | 24 | 0.110 |
Why?
| | Interview, Psychological | 1 | 2008 | 45 | 0.110 |
Why?
| | Prostate | 1 | 2008 | 28 | 0.110 |
Why?
| | Patient Selection | 1 | 2010 | 227 | 0.110 |
Why?
| | Graft Survival | 1 | 2008 | 105 | 0.110 |
Why?
| | Focus Groups | 1 | 2008 | 77 | 0.110 |
Why?
| | Abscess | 1 | 1988 | 20 | 0.110 |
Why?
| | Prejudice | 1 | 2008 | 38 | 0.110 |
Why?
| | Urography | 1 | 2007 | 4 | 0.110 |
Why?
| | Drug Combinations | 3 | 1993 | 84 | 0.110 |
Why?
| | Trauma Severity Indices | 1 | 2007 | 15 | 0.110 |
Why?
| | Cystoscopy | 1 | 2007 | 4 | 0.110 |
Why?
| | Accidents, Traffic | 1 | 2007 | 26 | 0.110 |
Why?
| | Wisconsin | 1 | 2007 | 5 | 0.110 |
Why?
| | Rectum | 1 | 2007 | 63 | 0.100 |
Why?
| | Interpersonal Relations | 1 | 2008 | 106 | 0.100 |
Why?
| | Suture Techniques | 1 | 2008 | 120 | 0.100 |
Why?
| | Health Care Surveys | 1 | 2007 | 72 | 0.100 |
Why?
| | Epidermal Growth Factor | 1 | 1986 | 34 | 0.100 |
Why?
| | Illinois | 1 | 2007 | 216 | 0.100 |
Why?
| | Heptanoic Acids | 1 | 2006 | 5 | 0.100 |
Why?
| | Patient Education as Topic | 1 | 2008 | 180 | 0.100 |
Why?
| | Pyrroles | 1 | 2006 | 20 | 0.090 |
Why?
| | Anticholesteremic Agents | 1 | 2006 | 21 | 0.090 |
Why?
| | Child, Preschool | 1 | 2008 | 711 | 0.090 |
Why?
| | Peptides | 1 | 1986 | 109 | 0.090 |
Why?
| | 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2005 | 2 | 0.090 |
Why?
| | Therapeutic Irrigation | 2 | 1995 | 54 | 0.080 |
Why?
| | Transplantation, Heterologous | 1 | 2003 | 22 | 0.080 |
Why?
| | Prolactin | 1 | 2003 | 2 | 0.080 |
Why?
| | Pituitary Diseases | 1 | 2003 | 3 | 0.080 |
Why?
| | Fertilization in Vitro | 1 | 2003 | 3 | 0.080 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2003 | 3 | 0.080 |
Why?
| | Pituitary Gland | 1 | 2003 | 14 | 0.080 |
Why?
| | Drug Administration Routes | 1 | 2003 | 9 | 0.080 |
Why?
| | Electricity | 1 | 2003 | 10 | 0.080 |
Why?
| | Tissue Distribution | 1 | 2003 | 46 | 0.080 |
Why?
| | Steroids | 1 | 2003 | 27 | 0.080 |
Why?
| | Fatal Outcome | 1 | 2003 | 70 | 0.080 |
Why?
| | Epinephrine | 1 | 2003 | 28 | 0.080 |
Why?
| | Venous Thrombosis | 1 | 2003 | 42 | 0.070 |
Why?
| | Vascular Diseases | 1 | 2002 | 41 | 0.070 |
Why?
| | Cadaver | 1 | 2003 | 307 | 0.070 |
Why?
| | Immediate-Early Proteins | 1 | 2002 | 6 | 0.070 |
Why?
| | Calcium | 1 | 1986 | 479 | 0.070 |
Why?
| | Repressor Proteins | 1 | 2002 | 46 | 0.070 |
Why?
| | Sex Counseling | 1 | 2000 | 1 | 0.070 |
Why?
| | Hemodynamics | 2 | 2012 | 99 | 0.070 |
Why?
| | Decision Trees | 1 | 2000 | 21 | 0.070 |
Why?
| | Clinical Laboratory Techniques | 1 | 2000 | 19 | 0.070 |
Why?
| | Drug Interactions | 1 | 2000 | 68 | 0.070 |
Why?
| | Gene Expression Regulation | 1 | 2002 | 312 | 0.060 |
Why?
| | Urination | 1 | 1998 | 4 | 0.060 |
Why?
| | Fascia | 1 | 1998 | 9 | 0.060 |
Why?
| | Reproductive Techniques | 1 | 1998 | 1 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2000 | 366 | 0.060 |
Why?
| | Mucous Membrane | 1 | 1998 | 38 | 0.060 |
Why?
| | Heterografts | 1 | 2017 | 12 | 0.050 |
Why?
| | Urodynamics | 1 | 1997 | 4 | 0.050 |
Why?
| | Incidence | 1 | 2000 | 690 | 0.050 |
Why?
| | Global Health | 1 | 2018 | 51 | 0.050 |
Why?
| | Adipose Tissue | 1 | 1998 | 67 | 0.050 |
Why?
| | Head and Neck Neoplasms | 1 | 1979 | 127 | 0.050 |
Why?
| | Conscious Sedation | 1 | 1997 | 5 | 0.050 |
Why?
| | Anesthesia, Local | 1 | 1997 | 5 | 0.050 |
Why?
| | Internet | 1 | 2018 | 83 | 0.050 |
Why?
| | Societies, Medical | 1 | 2018 | 170 | 0.050 |
Why?
| | Ecchymosis | 1 | 1995 | 2 | 0.050 |
Why?
| | Ephedrine | 1 | 1995 | 4 | 0.050 |
Why?
| | Blood Flow Velocity | 1 | 1995 | 25 | 0.050 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 82 | 0.050 |
Why?
| | Angiography | 1 | 1995 | 41 | 0.050 |
Why?
| | Data Interpretation, Statistical | 1 | 1995 | 94 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 1996 | 291 | 0.040 |
Why?
| | Knowledge Bases | 1 | 2014 | 3 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 1997 | 574 | 0.040 |
Why?
| | Thrombosis | 1 | 1995 | 61 | 0.040 |
Why?
| | Reference Values | 1 | 1994 | 243 | 0.040 |
Why?
| | Cerebral Angiography | 1 | 2014 | 59 | 0.040 |
Why?
| | Australia | 1 | 2013 | 38 | 0.040 |
Why?
| | Endovascular Procedures | 1 | 2014 | 60 | 0.040 |
Why?
| | Administration, Intravesical | 1 | 1993 | 6 | 0.040 |
Why?
| | Ureteral Obstruction | 1 | 1993 | 15 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 369 | 0.040 |
Why?
| | Urologic Diseases | 1 | 1993 | 5 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 1993 | 37 | 0.040 |
Why?
| | Blood Transfusion | 1 | 1993 | 54 | 0.040 |
Why?
| | Methods | 1 | 1992 | 25 | 0.040 |
Why?
| | Edema | 1 | 1992 | 35 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2012 | 44 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2012 | 68 | 0.040 |
Why?
| | Veins | 1 | 1991 | 7 | 0.030 |
Why?
| | Color | 1 | 1991 | 8 | 0.030 |
Why?
| | Sleep | 1 | 1994 | 273 | 0.030 |
Why?
| | Survival Analysis | 1 | 2012 | 360 | 0.030 |
Why?
| | Laparoscopy | 1 | 1993 | 168 | 0.030 |
Why?
| | Rats, Sprague-Dawley | 1 | 1992 | 486 | 0.030 |
Why?
| | Vasoconstriction | 1 | 1990 | 16 | 0.030 |
Why?
| | Drug Evaluation | 1 | 1990 | 57 | 0.030 |
Why?
| | Rats | 1 | 1992 | 938 | 0.030 |
Why?
| | Acrolein | 1 | 1989 | 1 | 0.030 |
Why?
| | Clostridium | 1 | 1968 | 2 | 0.030 |
Why?
| | Blood | 1 | 1968 | 24 | 0.030 |
Why?
| | Protease Inhibitors | 1 | 1968 | 21 | 0.030 |
Why?
| | Drainage | 1 | 1988 | 52 | 0.030 |
Why?
| | Radiography | 1 | 1991 | 686 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2012 | 698 | 0.030 |
Why?
| | Area Under Curve | 1 | 2007 | 70 | 0.030 |
Why?
| | Ambulatory Care | 1 | 1988 | 79 | 0.030 |
Why?
| | Prostheses and Implants | 1 | 1989 | 160 | 0.030 |
Why?
| | Prostaglandins E | 1 | 1986 | 5 | 0.030 |
Why?
| | Transforming Growth Factors | 1 | 1986 | 2 | 0.030 |
Why?
| | Dinoprostone | 1 | 1986 | 28 | 0.020 |
Why?
| | Parathyroid Hormone | 1 | 1986 | 21 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2006 | 41 | 0.020 |
Why?
| | Kinetics | 1 | 1986 | 279 | 0.020 |
Why?
| | Mice | 2 | 1986 | 1608 | 0.020 |
Why?
| | Minimally Invasive Surgical Procedures | 1 | 2007 | 251 | 0.020 |
Why?
| | Empty Sella Syndrome | 1 | 2003 | 2 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2007 | 1138 | 0.020 |
Why?
| | Pituitary Neoplasms | 1 | 2003 | 14 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 1988 | 781 | 0.020 |
Why?
| | Adenoma | 1 | 2003 | 42 | 0.020 |
Why?
| | Inhibitor of Differentiation Protein 2 | 1 | 2002 | 1 | 0.020 |
Why?
| | Early Growth Response Protein 1 | 1 | 2002 | 4 | 0.020 |
Why?
| | Pancreatic Elastase | 1 | 2002 | 3 | 0.020 |
Why?
| | Ubiquitin | 1 | 2002 | 34 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2002 | 25 | 0.020 |
Why?
| | Terminology as Topic | 1 | 2001 | 50 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 213 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2002 | 121 | 0.020 |
Why?
| | Down-Regulation | 1 | 2002 | 133 | 0.020 |
Why?
| | Up-Regulation | 1 | 2002 | 187 | 0.020 |
Why?
| | Transcription Factors | 1 | 2002 | 165 | 0.020 |
Why?
| | Gene Expression | 1 | 2002 | 245 | 0.020 |
Why?
| | Palliative Care | 1 | 2001 | 103 | 0.020 |
Why?
| | Comorbidity | 1 | 2002 | 473 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2002 | 221 | 0.020 |
Why?
| | Cytokines | 1 | 2002 | 332 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2002 | 751 | 0.010 |
Why?
| | Eponyms | 1 | 1998 | 2 | 0.010 |
Why?
| | History, 16th Century | 1 | 1998 | 4 | 0.010 |
Why?
| | History, 18th Century | 1 | 1998 | 11 | 0.010 |
Why?
| | Wound Healing | 1 | 1979 | 160 | 0.010 |
Why?
| | Cryptorchidism | 1 | 1993 | 4 | 0.010 |
Why?
| | Prostate-Specific Antigen | 1 | 1993 | 17 | 0.010 |
Why?
| | Lymphatic Metastasis | 1 | 1993 | 96 | 0.010 |
Why?
| | Forecasting | 1 | 1993 | 116 | 0.010 |
Why?
| | Ducks | 1 | 1968 | 1 | 0.010 |
Why?
| | Chromatography | 1 | 1968 | 6 | 0.010 |
Why?
| | Chromatography, Gel | 1 | 1968 | 16 | 0.010 |
Why?
| | Trypsin Inhibitors | 1 | 1968 | 2 | 0.010 |
Why?
| | Goats | 1 | 1968 | 11 | 0.010 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1968 | 10 | 0.010 |
Why?
| | Hot Temperature | 1 | 1968 | 27 | 0.010 |
Why?
| | Guinea Pigs | 1 | 1968 | 69 | 0.010 |
Why?
| | Horses | 1 | 1968 | 28 | 0.010 |
Why?
| | Cricetinae | 1 | 1968 | 51 | 0.010 |
Why?
| | Swine | 1 | 1968 | 96 | 0.010 |
Why?
| | Chickens | 1 | 1968 | 52 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1968 | 182 | 0.010 |
Why?
| | Cattle | 1 | 1968 | 249 | 0.010 |
Why?
| | Rabbits | 1 | 1968 | 314 | 0.010 |
Why?
|
|
Levine's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|